# SG1906 for CLDN18.2-Positive Solid Tumors

> **NCT05857332** · PHASE1 · RECRUITING · sponsor: **Hangzhou Sumgen Biotech Co., Ltd.** · enrollment: 60 (estimated)

## Conditions studied

- Locally Advanced Unresectable or Metastatic Solid Tumors

## Interventions

- **DRUG:** SG1906

## Key facts

- **NCT ID:** NCT05857332
- **Lead sponsor:** Hangzhou Sumgen Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-30
- **Primary completion:** 2027-02-28
- **Final completion:** 2027-08-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05857332

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05857332, "SG1906 for CLDN18.2-Positive Solid Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05857332. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*